Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Neoadjuvant Pilot Phase II Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab in Stage IIIB/C/D Melanoma Patients With an Integrated Imaging Biomarker

NCT04401995 is registered in ClinicalTrials.gov with Diwakar Davar as lead sponsor.

NCT NCT04401995
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04401995 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Neoadjuvant Pilot Phase II Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab in Stage IIIB/C/D Melanoma Patients With an Integrated Imaging Biomarker
Lead sponsor
Diwakar Davar
Phase
Phase 2
Overall status
Completed
Start date
September 2, 2020
Completion date
August 16, 2024
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma